Gary Nabel

“For 2001, the two products are obviously in different stages. For MDX 2001, we've treated 41 patients as of the end of September. What we're doing at this point is we think we're probably fairly close to the maximum tolerated dose by the IV route.”

“Yeah, I think you mean 3001 for the INVIVO CAR T program, if I understood the question correctly. So for 3001, our initial thought is that we would pursue studies in autoimmune disease, and there the targeting that we would be looking for would be to B cells.”

“Well, you know, obviously the first order of business is to show acceptable toxicity, and that's where the early phase one data becomes important. We don't expect to see anything different from other candidates that have gone forward, but we need to get through that first.”

“We are in our fifth patient at the fifth dose level. And again, when the suitable observation period has been complete, then we'd go on to the next.”

“As Elias and Phil mentioned, we have the approval to proceed. Currently, we are in the process of setting up sites and looking to enroll patients in the trial. As Elias noted in his comments, we are optimistic that this will occur by the end of the quarter, and we are striving to expedite the process if we can.”